MGC
Pharmaceuticals Ltd
Results
of General Meeting
18 March
2024
ASX, LSE:
MXC
MGC Pharmaceuticals Ltd ('MGC
Pharma' or 'the Company')
would like to announce the voting
results from the Company's General Meeting of shareholders, held
today Monday, 18 March 2024.
The Company
advises that all motions put to the meeting were voted by poll,
with all resolutions carried.
Details of
the results can be found in the following URL:
https://www.investi.com.au/api/announcements/mxc/b11d4b33-9bd.pdf
As a
result of Resolution 1 having been passed at the meeting,
shareholders have granted approval for the Company to change its
name to Argent Biopharma Ltd, reflecting the final step in a
comprehensive restructuring.
The Company is currently in the process of
notifying the Australian Securities and Investments Commission
(ASIC) of the change of name and will update
shareholders with additional details prior to the effective
date.
-Ends-
Authorised for release by the board of directors, for further
information please contact:
About MGC Pharma
MGC
Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a prominent European
pharmaceutical company with a strong commitment to creating
accessible and ethically produced cutting-edge medicines. Our
approach combines in-house research with innovative technologies,
all aimed at discovering and producing treatments for currently
unmet medical conditions.
The
company's founders and executives are distinguished figures in the
global pharmaceutical industry. Our central business strategy
revolves around the development and supply of innovative medicines,
responding to the increasing demand in the medical markets of
Europe, North America, and Australasia.
MGC Pharma
maintains a robust development pipeline that addresses two
prevalent medical conditions, with additional products currently in
the developmental stages. We've established strategic partnerships
with renowned institutions and academia, fostering the optimization
of our medicines' development. These medicines are produced in our
EU-GMP Certified manufacturing facilities, ensuring the highest
quality standards.
With a
growing patient base in key regions like the USA, UK, Australia,
and Ireland, MGC Pharma has also built a global distribution
network through a wide-reaching group of commercial partners. This
extensive network places us in a prime position to supply the
global market effectively.
Follow us
through our social media channels:
LinkedIn:
MGC Pharmaceuticals Ltd.
Twitter:
@MGC_Pharma
Facebook:
@mgcpharmaceuticals
Instagram:
@mgc_pharma